Literature DB >> 2237905

Tumors of the heart. Experiences at the Giessen University Clinic.

R Moosdorf1, H H Scheld, F W Hehrlein.   

Abstract

Of 54 cardiac tumors operated upon in our clinic, 42 were classified as benign and only 12 as malignant. The major part of the benign tumors were myxoma, mainly located in the left atrium. While smaller tumors could be treated by local resections, extensive resections were necessary in 14 patients with greater tumors followed by reconstructions of the pulmonary and caval vein, mitral and tricuspid valve, and major parts of the right and left ventricular wall. In one patient with a huge benign myxoma, tumor exposition and total resection could only be achieved by an autotransplantation of the heart. While mortality after surgical therapy of benign tumors was only 1.4% (1/42) within a mean follow-up time of 48 months, the prognosis of malignant tumors is still fatal with a mortality of 50% (6/12) within a mean follow-up time of 24 months, despite additional chemotherapy or radiation.

Entities:  

Mesh:

Year:  1990        PMID: 2237905     DOI: 10.1055/s-2007-1014069

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  4 in total

1.  Right ventricular myxoma: report of a case.

Authors:  S Kinugasa; K Asada; T Kodama; Y Nishimoto; S Hasegawa; Y Sawada; N Matsuyama; T Morimoto; K Okamoto; S Sasaki
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  Role of magnetic resonance imaging for evaluation of tumors in the cardiac region.

Authors:  Tatsuro Kaminaga; Thoru Takeshita; Izumi Kimura
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

3.  Myxoma of the superior vena cava origin presented as a right atrial mass.

Authors:  Feridoun Sabzi; Babak Nasiri
Journal:  J Tehran Heart Cent       Date:  2013-10-28

Review 4.  Prevalence of primary cardiac tumor malignancies in retrospective studies over six decades: a systematic review and meta-analysis.

Authors:  Shuai He; Yide Cao; Wei Qin; Wen Chen; Li Yin; Hao Chai; Zhonghao Tao; Shaowen Tang; Zhibing Qiu; Xin Chen
Journal:  Oncotarget       Date:  2017-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.